Patents by Inventor Shancheng REN

Shancheng REN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and materials for identifying and treating bet inhibitor-resistant cancers
    Patent number: 11712439
    Abstract: This document provides methods and materials involved in identifying and treating mammals having a cancer resistant to BET inhibitors. For example, methods and materials for administering one or more AKT inhibitors in combination with one or more BET inhibitors to mammals identified as having a cancer resistant to treatment with one or more BET inhibitors in the absence of AKT inhibitors are provided.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: August 1, 2023
    Assignees: Mayo Foundation for Medical Education and Research, Shanghai Changhai Hospital
    Inventors: Haojie Huang, Yinghao Sun, Shancheng Ren
  • METHODS AND MATERIALS FOR IDENTIFYING AND TREATING BET INHIBITOR-RESISTANT CANCERS
    Publication number: 20210361653
    Abstract: This document provides methods and materials involved in identifying and treating mammals having a cancer resistant to BET inhibitors. For example, methods and materials for administering one or more AKT inhibitors in combination with one or more BET inhibitors to mammals identified as having a cancer resistant to treatment with one or more BET inhibitors in the absence of AKT inhibitors are provided.
    Type: Application
    Filed: August 9, 2018
    Publication date: November 25, 2021
    Inventors: Haojie Huang, Yinghao Sun, Shancheng Ren
  • PROSTATIC CANCER MARKER, PCDH9, AND APPLICATION THEREOF
    Publication number: 20200172980
    Abstract: The present invention provides a biomarker PCDH9 for molecular classification of prostate cancer and for evaluation of prostate cancer prognosis and uses thereof. The biomarker PCDH9 can be DNA or mRNA of PCDH9 or a protein encoded thereby. The present invention also provides a prostate cancer in vitro diagnostic product comprising a detection reagent of the biomarker PCDH9.
    Type: Application
    Filed: December 15, 2017
    Publication date: June 4, 2020
    Applicant: SHANGHAI CHANGHAI HOSPITAL
    Inventors: Yinghao SUN, Shancheng REN, Xiaolei SHI, Yasheng ZHU, Yue YANG
  • PROSTATIC CANCER MARKER, PLXNA1, AND APPLICATION THEREOF
    Publication number: 20200080156
    Abstract: The present invention provides an application of PLXNA1 as a biomarker for predicting the occurrence, development, and prognosis of prostate cancer and for distinguishing prostate cancer being progressive and with high malignancy. By detecting a change in a PLXNA1 DNA copy number, and expression levels of mRNA and a protein encoded thereby, a diagnosis and prognosis of prostate cancer are performed. The present invention also provides an application of PLXNA1 as a therapeutic target for prostate cancer. The present invention also provides a kit for diagnosing and predicting prostate cancer.
    Type: Application
    Filed: December 15, 2017
    Publication date: March 12, 2020
    Applicant: SHANGHAI CHANGHAI HOSPITAL
    Inventors: Yinghao SUN, Shancheng REN, Yasheng ZHU, Xiaolei SHI, Yue YANG